Gene Shigekawa, managing partner of MAZ World, shares their recent move to the Hong Kong Science and Technology Park (HKSTP) in 2017, the revolutionary ostrich-derived antibody they hope to further develop and commercialize, the strengths of Hong Kong as a biotech base for start-ups, and the huge potential for their technology in both beauty and healthcare, particularly preventative healthcare.
As a Japanese company, what prompted MAZ World’s move to Hong Kong and the Science and Technology Park (HKSTP)?
"We believe the innovation in antibody technology we bring can have a significant impact on society"
